MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
DENTSPLY SIRONA Operating Income 2011-2026 | XRAY
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DENTSPLY SIRONA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -879 M | -85 M | -937 M | 608 M | -3 M | 353 M | -958 M | -1.56 B | 455 M | 375 M | 446 M | 419 M | 382 M | 301 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 608 M | -1.56 B | -77.6 M |
Quarterly Operating Income DENTSPLY SIRONA
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -218 M | -128 M | 63 M | - | -462 M | 50 M | 42 M | - | -236 M | 80 M | -2 M | - | -1.22 B | 119 M | 97 M | - | 132 M | 154 M | 150 M | - | 82 M | -104 M | -125 M | 137 M | 110 M | 67.5 M | 47.3 M | 81.8 M | 45.5 M | -1.15 B | 68.7 M | -706 M | 108 M | -1.05 B | 84.2 M | 134 M | 127 M | 121 M | 72.7 M | 93.1 M | 98.6 M | 85.8 M | 97.7 M | 103 M | 110 M | 127 M | 106 M | 97.4 M | 105 M | 123 M | 93.9 M | - | 88.7 M | 109 M | 87.2 M | - | 39.8 M | 97 M | 98.6 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -1.22 B | -28.2 M |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M |  USA |
 |
Baxter International
BAX
|
14 M | $ 19.94 | 1.45 % | $ 10.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
-10.5 M | $ 8.05 | -2.07 % | $ 162 M | USA |
 |
Alcon
ALC
|
580 M | $ 80.14 | 1.44 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
-40 M | $ 37.41 | 2.77 % | $ 1.76 B | USA |
 |
electroCore
ECOR
|
-19.3 M | $ 6.53 | 3.82 % | $ 36 K | USA |
 |
ICU Medical
ICUI
|
43 M | $ 148.7 | 0.28 % | $ 3.63 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.21 | 1.37 % | $ 417 M | USA |
 |
InfuSystem Holdings
INFU
|
1.65 M | $ 8.74 | 2.7 % | $ 180 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 81.74 | 0.05 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
222 M | $ 76.43 | -3.0 % | $ 3.85 B | USA |
 |
Harvard Bioscience
HBIO
|
1.89 M | $ 0.57 | -2.96 % | $ 24.2 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 103.94 | -5.75 % | $ 5.03 B | USA |
 |
Repro Med Systems
KRMD
|
-10.3 M | $ 5.56 | -3.81 % | $ 254 M | USA |
 |
Isoray
ISR
|
-90.9 M | - | 0.03 % | $ 108 M | USA |
 |
iRhythm Technologies
IRTC
|
-116 M | $ 163.14 | 4.95 % | $ 5.09 B | USA |
 |
LeMaitre Vascular
LMAT
|
52.3 M | $ 85.13 | 2.15 % | $ 1.91 B | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 137.72 | 6.07 % | $ 7.34 B | USA |
 |
Merit Medical Systems
MMSI
|
156 M | $ 81.8 | 0.89 % | $ 4.76 B | USA |
 |
Intuitive Surgical
ISRG
|
2.35 B | $ 547.88 | -2.48 % | $ 195 B | USA |
 |
Microbot Medical
MBOT
|
-9.86 M | $ 2.16 | 1.89 % | $ 22 M |  Israel |
 |
Nephros
NEPH
|
-1.59 M | $ 4.4 | -0.51 % | $ 45.7 M | USA |
 |
Milestone Scientific
MLSS
|
-6.76 M | $ 0.29 | 0.99 % | $ 23.1 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
OraSure Technologies
OSUR
|
-28.2 M | $ 2.69 | 3.27 % | $ 200 M | USA |
 |
Envista Holdings Corporation
NVST
|
-1.04 B | $ 24.14 | 3.92 % | $ 4.16 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 40.05 | -0.72 % | $ 132 M | USA |
 |
Predictive Oncology
POAI
|
-10.9 M | $ 7.28 | 1.0 % | $ 39.7 M | USA |
 |
Pulse Biosciences
PLSE
|
-43.6 M | $ 14.3 | 1.06 % | $ 687 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 207.32 | 2.88 % | $ 59.6 B | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 161.81 | -3.29 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
1 B | $ 259.06 | 1.71 % | $ 37.8 B | USA |
 |
STERIS plc
STE
|
867 M | $ 264.04 | 1.58 % | $ 26 B | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 24.28 | 1.59 % | $ 1.12 B | USA |
 |
Stereotaxis
STXS
|
-21.8 M | $ 2.76 | 2.8 % | $ 223 M | USA |
 |
Retractable Technologies
RVP
|
-21.1 M | $ 0.72 | -2.7 % | $ 21.6 M | USA |
 |
STAAR Surgical Company
STAA
|
-12.6 M | $ 21.52 | 1.82 % | $ 1.06 B | USA |
 |
Utah Medical Products
UTMD
|
16.8 M | $ 58.97 | 0.7 % | $ 214 M | USA |
 |
Teleflex Incorporated
TFX
|
151 M | $ 103.33 | -0.54 % | $ 4.84 B | USA |
 |
West Pharmaceutical Services
WST
|
570 M | $ 276.83 | 1.84 % | $ 20.2 B | USA |